Difference between revisions of "Fotemustine (Muphoran)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "http://www.cancer.gov" to "https://www.cancer.gov") |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | From the [ | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=38865 NCI Drug Dictionary]: A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier. |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
| − | *[[Hodgkin lymphoma]] | + | *[[Classical Hodgkin lymphoma]] |
*[[Melanoma]] | *[[Melanoma]] | ||
**[[CNS melanoma]] | **[[CNS melanoma]] | ||
**[[Uveal melanoma]] | **[[Uveal melanoma]] | ||
| + | ==History of changes in EMA indication== | ||
| + | *1989-04-14: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Brand names:''' Muphoran, Mustophoran | *'''Brand names:''' Muphoran, Mustophoran | ||
| Line 17: | Line 19: | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Classical Hodgkin lymphoma medications]] |
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Uveal melanoma medications]] | [[Category:Uveal melanoma medications]] | ||
| − | [[Category:EMA approved | + | [[Category:EMA approved in 1989]] |
Latest revision as of 20:21, 27 June 2024
Mechanism of action
From the NCI Drug Dictionary: A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.
Diseases for which it is used
History of changes in EMA indication
- 1989-04-14: EURD
Also known as
- Brand names: Muphoran, Mustophoran